Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Qingdao Central Hospital · 2015
ClinicalTrials.gov · Datasets · License: Public Domain · 2015
Open Source ↗
progression-free-survival
progression free survival, osimertinib, egfr t790m resistant mutation, docetaxel, bevacizumab, non small cell lung, interventional, phase2, phase3
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 889967
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.